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Abstract
Background and Aims Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during 
oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of 
oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks 
post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon 
(PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120.
Methods In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive 
TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), 
TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed.
Results Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C 
(0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates 
in group C (P < 0.001 for both) or group D (HBsAg loss: P = 0.002; HBsAg seroconversion: P < 0.001).
Conclusions The results of this analysis confirm the results from earlier time points which demonstrate the increased rate 
of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving 
either monotherapy.
Keywords Chronic hepatitis B · HBsAg seroconversion · HBsAg loss · Virological response
Introduction
Infection with hepatitis B virus (HBV) remains an impor-
tant global public health problem associated with significant 
morbidity and mortality [1]. Worldwide, an estimated 240 
million persons have chronic hepatitis B (CHB) with the 
highest prevalence in Africa and Asia [2]. In these regions, 
HBV is endemic with the majority of infections being 
acquired perinatally or in early childhood [3]. All patients 
with CHB infection are at increased risk of progression to 
cirrhosis, hepatic decompensation, and hepatocellular car-
cinoma (HCC); in fact, HBV infection is thought to account 
for approximately 30% of cirrhosis cases and 50% of HCC 
cases worldwide [1, 4]. The goal of oral antiviral treatment 
for CHB is to achieve and maintain undetectable HBV DNA 
levels, thus lowering risk of disease progression [1]. Inhibi-
tion of viral replication improves clinical outcomes in the 
majority of patients by preventing HBV-induced necroin-
flammation and fibrotic liver processes; however, it does not 
address intrahepatic viral persistence as cccDNA remains 
within hepatocytes and therefore eradication of HBV is not 
achieved with currently available agents [5].
Sang Hoon Ahn and Patrick Marcellin are joint first authors.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1062 0-018-5251-9) contains 
supplementary material, which is available to authorized users.
 * Patrick Marcellin 
 patrick.marcellin@bjn.aphp.fr
 * Henry L. Y. Chan 
 hlychan@cuhk.edu.hk
Extended author information available on the last page of the article
3488 Digestive Diseases and Sciences (2018) 63:3487–3497
1 3
Loss of hepatitis B surface antigen (HBsAg) is the clos-
est to clinical cure of CHB and is regarded as the optimal 
endpoint of therapy, indicating complete response and func-
tional remission of the virus [1]. However, HBsAg loss is 
rarely achieved with the current spectrum of antivirals. For 
example, only 13% of patients treated with the nucleotide 
reverse-transcriptase inhibitor tenofovir disoproxil fuma-
rate (TDF) over an 8-year period achieved loss of HBsAg 
[6]. In the absence of HBsAg loss, lifelong therapy with 
nucleos(t)ide analogs (NAs) is required to maintain virologi-
cal suppression.
A current unmet need in CHB management is therefore 
achieving HBsAg loss with finite therapy, thereby allowing 
discontinuation of oral antiviral treatment. One therapeutic 
strategy that has been investigated as having the potential to 
allow finite therapy is combination of an NA with an immu-
nomodulator. The current analysis describes the long-term 
(week 120) efficacy and safety of stopping therapy in CHB 
patients treated with pegylated interferon (PEG-IFN) and 
TDF for 48 weeks. Initial results from this study demon-
strated that the combination regimen resulted in significantly 
higher rates of HBsAg loss (9.1% at week 72) than either 
continuous TDF (0%) or 48 weeks of PEG-IFN as mono-
therapy (2.8%) [7].
Patients and Methods
This is an analysis of data from study GS-US-174-0149, 
a randomised, open-label, active-controlled, multinational, 
superiority trial (NCT01277601). The full details of the 
study and its inclusion and exclusion criteria are detailed in 
the primary analysis published previously [7]. Briefly, the 
study enrolled patients aged 18–75 years with CHB who 
had not received treatment with either PEG-IFN or a NA 
inhibitor previously. The trial was approved by the Institu-
tional Review Board or Independent Ethics Committee at 
each site and was conducted according to the Declaration 
of Helsinki, Good Clinical Practice guidelines, and local 
regulatory requirements.
The primary endpoint of the trial was HBsAg loss at 
week 72, 24 weeks after stopping treatment in the finite 
therapy arms. The prespecified data analysis plan included 
an extended follow-up period of 48 weeks (up to week 120). 
Patients were randomly assigned 1:1:1:1 to one of four treat-
ment groups: TDF plus PEG-IFN for 48 weeks (group A); 
TDF plus PEG-IFN for 16 weeks followed by 32 weeks of 
TDF alone (group B); TDF alone for 120 weeks (group C); 
or PEG-IFN alone for 48 weeks (group D). Patients were 
stratified by hepatitis B “e” antigen (HBeAg) status and 
HBV genotype at screening. TDF was administered orally 
once daily at a dose of 300 mg, and PEG-IFN alfa-2a was 
administered subcutaneously weekly at a dose of 180 µg. 
During follow-up, any patient who developed either hepatic 
decompensation or virological or biochemical relapse was 
retreated with TDF monotherapy (300 mg once daily orally).
Study visit assessments included measurement of serum 
HBsAg (Architect assay; Abbott Diagnostics, lower limit of 
detection: 0.05 IU/mL) and serum HBV DNA (polymerase 
chain reaction-based 230 m2000sp/m2000rt; Abbott Diag-
nostics, lower limit of quantification: 15 IU/mL) in addi-
tion to standard laboratory, clinical, and safety assessments. 
HBsAg loss was determined using the Architect Qualitative 
II assay (Abbott Diagnostics, lower limit of detection 1 S/
CO).
Statistical Analysis
Full details of the statistical analyses have been reported 
previously [7]. In the current analysis, response to treatment 
was defined as HBsAg loss at week 120. All patients who 
received at least one dose of study drug were included in the 
efficacy and safety analyses. For the purpose of characteriz-
ing the full safety profile, all available data up to and beyond 
week 120 were included in the safety analysis.
In the primary analysis, the proportion of patients with 
HBsAg loss at week 72 was estimated by a Kaplan–Meier 
method and the prespecified data analysis plan also included 
long-term results (week 120). Kaplan–Meier estimates were 
calculated for HBsAg loss and HBsAg seroconversion at 
week 120 by baseline HBeAg status. Data for patients 
without HBsAg loss were censored at the last time point 
observed.
Comparisons between groups were made via stratified 
log-rank tests, by baseline HBeAg status and HBV genotype.
Results
Baseline Characteristics
The baseline characteristics of patients included in this study 
have been described previously [7]. These, along with demo-
graphics, were balanced across the four treatment groups. 
The majority of patients (57.8%) were HBeAg positive. 
Mean standard deviation (SD) of alanine aminotransferase 
(ALT) level, HBV DNA level, and baseline HBsAg level 
across all arms was 110 (117) U/L, 7.0  log10 (1.6) IU/mL, 
and 3.8 (0.8)  log10 IU/mL, respectively.
Serological Response at Week 120
At week 120, the Kaplan–Meier cumulative estimate of 
HBsAg loss was 10.4% for group A, 3.5% for group B, 0% 
for group C, and 3.5% for group D (Table 1). An increase 
in the proportion of patients with HBsAg loss occurred 
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at week 24 in group A, peaking at week 108. The rates of 
HBsAg loss and HBsAg seroconversion in group A were 
significantly higher than rates in group C (P < 0.001 for 
both) or group D (HBsAg loss: P = 0.002; HBsAg sero-
conversion: P < 0.001) (Fig. 1). The rates of HBsAg loss 
and HBsAg seroconversion in group B did not significantly 
differ from those in group C or group D.
At week 120, rates of HBeAg loss were 38.6%, 37.5%, 
20.2%, and 33.3% for groups A, B, C, and D, respec-
tively; HBeAg seroconversion rates were 29.5%, 35.0%, 
15.6%, and 25.0% for groups A, B, C, and D, respectively. 
Kaplan–Meier cumulative estimates of HBsAg loss and 
HBsAg seroconversion by baseline HBeAg status for 
groups A, B, C, and D are given in Table 2.
Of the 30 patients with HBsAg loss and/or seroconver-
sion at any time point up to week 120, 22 (73%) achieved 
and maintained HBsAg loss until their final time point 
[week 120 (n = 19); week 96 (n = 3)], with the major-
ity of these patients receiving combination therapy: 14 
(64%), 2 (10%), and 6 (27%) patients in groups A, B, and 
D, respectively. Seven patients (23%) achieved HBsAg 
loss followed by reversion, and one patient experienced 
reversion at weeks 72 and 96, before achieving HBsAg 
loss again. HBsAg reversions only occurred in treatment 
groups A (n = 4) and B (n = 4). The occurrence of rever-
sions in a small percentage of patients suggests that this 
subgroup would benefit from continued monitoring and 
long-term follow-up.
Table 1  Efficacy results at 
weeks 72 and 120
P values calculated using a stratified log-rank test
a Patients with missing data at analyzed time point were imputed as failures at each visit
Response Group A 
(n = 186)
TDF + PEG-
IFN for 
48 weeks
Group B (n = 184)
TDF + PEG-IFN for 
16 weeks, TDF for 
32 weeks
Group C (n = 185)
TDF for 120 weeks
Group D (n = 185)
PEG-IFN for 48 weeks
HBsAg loss
Kaplan–Meier estimate (%)
 Week 72 9.05 2.83 0 2.84
 Week 120 10.36 3.49 0 3.51
P values for week 120
 Versus group C < 0.001 NS
 Versus group D 0.002 NS
HBsAg seroconversion
Kaplan–Meier estimate (%)
 Week 72 8.05 0.56 0 2.87
 Week 120 10.08 0.56 0 2.87
P values for week 120
 Versus group C < 0.001 NS
 Versus group D < 0.001 NS
Mean HBsAg change from baseline,  log10 IU/mL (SD)
 Week 72 − 1.0 (1.77) − 0.3 (0.97) − 0.4 (0.60) − 0.6 (1.13)
 Week 120 − 2.4 (2.35) − 0.8 (1.53) − 0.4 (0.66) − 1.1 (1.60)
HBV DNA < 15 IU/mL [n/N (%)]a
 Week 72 13/144 (9.0) 6/131 (4.6) 133/185 (71.9) 6/128 (4.7)
 Week 120 18/74 (24.3) 5/69 (7.2) 139/185 (75.1) 5/68 (7.4)
HBeAg loss [n/N (%)]a
 Week 72 27/76 (35.5) 20/61 (32.8) 16/109 (14.7) 21/64 (32.8)
 Week 120 17/44 (38.6) 15/40 (37.5) 22/109 (20.2) 12/36 (33.3)
HBeAg seroconversion [n/N (%)]a
 Week 72 22/76 (28.9) 19/61 (31.1) 14/109 (12.8) 20/64 (31.3)
 Week 120 13/44 (29.5) 14/40 (35.0) 17/109 (15.6) 9/36 (25.0)
ALT normalization [n/N (%)]a
 Week 72 51/124 (41.1) 48/117 (41.0) 86/183 (47.0) 41/118 (34.7)
 Week 120 28/73 (38.4) 21/68 (30.9) 88/183 (48.1) 21/68 (30.9)
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Mean HBsAg decline from baseline to week 120 was 
greater in group A (2.4  log10 IU/mL) than in groups B, C, 
and D (0.8, 0.4, and 1.1  log10 IU/mL, respectively) (Fig. 2).
Virological and Biochemical Response at Week 120
The changes in HBV DNA and ALT levels over time are 
shown in Fig. 3a, b. The percentage of patients in group A 
with HBV DNA levels < 15 IU/mL and ALT normalization 
at week 120 was 24% and 38%, respectively.
For all genotypes, HBV DNA remained suppressed at 
week 120 in patients receiving continuous TDF (Table 2).
TDF Retreatment Outcomes
Of the 555 patients randomised to the groups with treatment 
ending at week 48, 344 met the criteria for TDF retreatment 
through to week 120: 112/186 patients (60.2%) from group 
A; 115/184 patients (62.5%) from group B, and 117/185 
patients (63.2%) from group D. One patient from group D 
(1/117, 0.9%) who required TDF retreatment after week 48 
achieved HBsAg loss at week 120. This patient was retreated 
from week 56 and was HBeAg negative from week 58 and 
HBsAg negative from week 108; they did not achieve 
HBsAg seroconversion.
At week 120, 16/64 (25.0%), 15/65 (23.1%), and 13/70 
(18.6%) patients in groups A, B, and D, respectively, 
who had been retreated after stopping therapy at week 48 
achieved HBeAg loss and 14/64 (21.9%), 10/65 (15.4%), 
and 12/70 (17.1%) patients in groups A, B, and D had 
HBeAg seroconversion, respectively.
Safety Profile
The majority of patients in each treatment group experi-
enced adverse events: group A: 88%; group B: 88%; group 
C: 70%; and group D 92% (Table 3). The most frequently 
occurring adverse events in groups A, B, and D were head-
ache, alopecia, pyrexia, and fatigue (> 20% in either treat-
ment group). In group C, fatigue and nasopharyngitis were 
the most frequently occurring adverse events (> 10%). 
Among patients in groups A, B, and D who were sub-
sequently retreated with TDF alone, the rates of adverse 
events during retreatment were 40%, 41%, and 49%, 
respectively. Rates of serious adverse events were 11%, 
10%, 7%, and 10% in groups A, B, C, and D, respectively, 
and 6%, 3%, and 5% in groups A, B, and D, respectively, 
among those patients who were treated with TDF. The 
percentage of patients who discontinued treatment due to 
adverse events were 4%, 2%, 0%, and 8% in groups A, B, 
C, and D, respectively. One patient who was retreated with 
TDF monotherapy discontinued due to adverse events.
Fig. 1  Effect of TDF and PEG-IFN as combination or monotherapy 
on HBsAg loss. The rate of HBsAg loss in group A was significantly 
higher than rates in group C (P < 0.001) or group D (P = 0.002). The 
rate of HBsAg loss in group B did not significantly differ from that in 
group C or group D
3491Digestive Diseases and Sciences (2018) 63:3487–3497 
1 3
Table 2  Efficacy results at week 
120 by baseline HBeAg status 
and genotype
Response Group A 
(n = 186)
TDF + PEG-
IFN for 
48 weeks
Group B (n = 184)
TDF + PEG-IFN for 
16 weeks, TDF for 
32 weeks
Group C (n = 185)
TDF for 120 weeks
Group D (n = 185) 
PEG-IFN
for 48 weeks
HBsAg loss, Kaplan–Meier estimate (%)
 Overall 10.36 3.49 0 3.51
 HBeAg positive 9.73 5.15 0 5.23
 HBeAg negative 10.99 1.32 0 1.28
HBsAg seroconversion, Kaplan–Meier estimate (%)
 Overall 10.08 0.56 0 2.87
 HBeAg positive 10.41 0.97 0 4.10
 HBeAg negative 9.65 0 0 1.28
Mean HBsAg change from baseline,  log10 IU/mL (SD)
 Overall − 2.4 (2.4) − 0.8 (1.5) − 0.4 (0.7) − 1.1 (1.6)
 Genotype A − 4.2 (2.3) – − 0.7 (1.2) 0.0 (0.6)
 Genotype B − 2.2 (2.1) − 1.0 (1.0) − 0.7 (0.6) − 1.2 (1.2)
 Genotype C − 1.5 (2.2) − 0.4 (1.5) − 0.4 (0.7) − 1.1 (1.7)
 Genotype D − 2.0 (2.3) − 1.6 (2.6) − 0.2 (0.4) − 1.5 (2.9)
 HBeAg positive − 2.2 (2.6) − 1.2 (1.9) − 0.7 (0.7) − 1.3 (2.1)
 HBeAg negative − 2.5 (2.1) − 0.4 (0.9) − 0.1 (0.4) − 1.0 (1.1)
Mean HBV DNA change from baseline,  log10 IU/mL (SD)
 Overall − 4.2 (2.1) − 4.3 (2.0) − 5.7 (1.6) − 3.5 (2.0)
 Genotype A − 4.0 (1.9) – − 5.1 (2.1) − 1.9 (2.0)
 Genotype − 4.7 (2.0) − 4.2 (2.5) − 5.8 (1.4) − 3.3 (1.8)
 Genotype C − 4.2 (2.9) − 4.4 (1.5) − 5.9 (1.6) − 3.4 (2.3)
 Genotype D − 4.0 (1.8) − 4.1 (3.0) − 5.3 (1.7) − 5.1 (1.9)
 HBeAg positive − 5.5 (1.6) − 5.3 (1.5) − 6.6 (1.2) − 4.9 (1.6)
 HBeAg negative − 2.9 (1.7) − 3.4 (1.9) − 4.5 (1.3) − 2.5 (1.8)
Fig. 2  HBsAg decline from baseline to week 120. Data shown are mean ± 95% confidence intervals. Group A versus group B, P < 0.001; group 
A versus group C, P < 0.001; group A versus group D, P < 0.001
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Discussion
In patients with HBeAg-positive and HBeAg-negative CHB, 
without advanced liver disease, the rate of HBsAg loss at 
week 120 was significantly higher in patients receiving com-
bination therapy with TDF plus PEG-IFN for 48 weeks com-
pared with those receiving monotherapy with either TDF or 
PEG-IFN alone, or PEG-IFN plus TDF for 16 weeks fol-
lowed by TDF alone for 32 weeks. The rates of HBsAg loss 
increased in the combination therapy group from 9.1% at 
week 72 (24 weeks post-treatment) to 10.4% at week 120 
(72 weeks post-treatment).
The need for a well-tolerated, finite therapeutic option 
for patients with CHB, ideally resulting in HBsAg loss, 
Fig. 3  a Mean HBV DNA  (log10 IU/mL) (U/L) and b mean ALT (U/L) (95% confidence intervals shown)
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Table 3  Treatment discontinuations and adverse events
Variable Group A (n = 186)
TDF + PEG-IFN for 48 weeks
Group B (n = 184)
TDF + PEG-IFN for 16 weeks, 
then TDF for 32 weeks
Group C 
(n = 185)
TDF for 
120 weeks
Group D (n = 185)
PEG-IFN for 48 weeks
All time points 
without TDF 
retreatment
(N = 186)
All time 
points on 
TDF 
retreatment
(N = 112)
All time points 
without TDF 
retreatment
(N = 184)
All time 
points on 
TDF 
retreatment
(N = 115)
Continued 
TDF treatment 
(N = 185)
All time points 
without TDF 
retreatment
(N = 185)
All time points on 
TDF retreatment
(N = 117)
Any treatment-
emergent 
adverse event—
no. of patients 
(%)a
163 (88) 45 (40) 161 (88) 47 (41) 129 (70) 170 (92) 57 (49)
Any treatment-
emergent, 
treatment-
related adverse 
event—no. of 
patients (%)a
152 (82) 3 (3) 138 (75) 5 (4) 34 (18) 153 (83) 13 (11)
Any treatment-
emergent, 
serious adverse 
event—no. of 
patients (%)
21 (11) 7 (6) 18 (10) 3 (3) 13 (7) 18 (10) 6 (5)
Discontinuation 
of treatment 
due to adverse 
events—no. (%)
8 (4) 1 (1) 4 (2) 0 0 15 (8) 0
Common adverse 
events—no. of 
patients (%)b
54 (29) 3 (3) 37 (20) 3 (3) 16 (9) 52 (28) 4 (3)
 Headache 46 (25) 0 32 (17) 1 (1) 2 (1) 45 (24) 1 (1)
 Alopecia 39 (21) 1 (1) 36 (20) 1 (1) 8 (4) 43 (23) 2 (2)
 Pyrexia 40 (22) 2 (2) 33 (18) 4 (4) 21 (11) 41 (22) 6 (5)
 Fatigue 23 (12) 0 36 (20) 2 (2) 2 (1) 18 (10) 0
 Decreased 
appetite
29 (16) 0 36 (20) 1 (1) 2 (1) 35 (19) 1 (1)
 Myalgia 26 (14) 0 24 (13) 3 (3) 11 (6) 13 (7) 6 (5)
 Nausea 14 (8) 0 14 (8) 2 (2) 4 (2) 21 (11) 0
 Pruritus 20 (11) 0 9 (5) 1 (1) 4 (2) 12 (7) 1 (1)
 Asthenia 20 (11) 0 12 (7) 1 (1) 2 (1) 7 (4) 3 (3)
 Malaise 20 (11) 0 18 (10) 1 (1) 9 (5) 17 (9) 4 (4)
 Dizziness 20 (11) 1 (1) 17 (9) 1 (1) 1 (1) 9 (5) 2 (2)
 Rash 13 (7) 2 (2) 10 (5) 0 11 (6) 19 (10) 4 (3)
 Diarrhea 19 (10) 0 17 (9) 0 10 (5) 17 (9) 2 (2)
 Influenza-like 
illness
19 (10) 3 (3) 14 (8) 1 (1) 6 (3) 18 (10) 2 (2)
 Insomnia 19 (10) 3 (3) 14 (8) 1 (1) 6 (3) 18 (10) 2 (2)
 Psychiatric 
 disordersc
10 (5) 3 (3) 9 (5) 9 (8) 16 (9) 10 (5) 5 (4)
 Nasopharyngitis 5 (3) 3 (3) 16 (9) 3 (3) 20 (11) 6 (3) 3 (3)
Grade 3/4 laboratory abnormalities—no. of patients (%)
 Anemia 8 (4) 1 (1) 3 (2) 0 2 (1) 4 (2) 1 (1)
 Lymphopenia 12 (6) 1 (1) 7 (4) 0 7 (4) 11 (6) 1 (1)
 Neutropenia 30 (16) 1 (1) 21 (11) 3 (3) 3 (2) 27 (15) 2 (2)
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has been recognized for many years. Recent research has 
focused on identifying patients with maintained virologi-
cal suppression during NA therapy who could sustain this 
level of control after stopping therapy [8, 9]. For HBeAg-
positive patients, achievement of HBeAg seroconversion 
is associated with improved outcomes [10, 11] and inter-
national guidelines highlight that discontinuation of NAs 
could be considered in patients who have demonstrated 
HBeAg seroconversion and undetectable levels of HBV 
DNA for at least 6 months [1, 2, 12]. However, there is a 
risk of relapse following discontinuation of therapy [13], 
and therefore, continuation of therapy even after HBeAg 
seroconversion is still an approach adopted by many phy-
sicians. For HBeAg-negative patients, the only endpoint 
associated with improved long-term outcomes is HBsAg 
loss and therefore guidelines state that treatment should 
not be stopped in these patients until achievement of this 
endpoint [1, 2, 12]. As HBsAg loss occurs infrequently, 
this means lifelong therapy for most HBeAg-negative 
patients. However, there are increasing data showing the 
potential for stopping therapy in HBeAg-negative patients 
with long-term virological suppression. Hadziyannis et al. 
[8] reported HBsAg loss rates of 39% 6 years after stop-
ping adefovir dipivoxil therapy in patients who had been 
virologically suppressed for at least 4 years. Virological 
control was maintained off therapy in 55% of patients and 
HBsAg seroconversion achieved by 27%. A similar study 
in HBeAg-negative patients with virological suppression 
with TDF for at least 3.5 years demonstrated that 62% of 
patients remained off therapy at week 144 and HBsAg loss 
was achieved by 19% of patients at this time point [9].
In contrast to the studies described above, the current trial 
was designed to determine whether combination therapy 
with an immune modulator and an NA could provide a finite 
therapeutic option for previously untreated patients. Combi-
nation therapy has been considered since the initial introduc-
tion of NAs, based on the hypothesis that both immunomod-
ulatory and virological activity may improve rates of HBsAg 
loss, enhancing the early virological response. The phase 3 
studies of PEG-IFN alfa-2a included an arm which com-
bined PEG-IFN with the first-generation NA, lamivudine 
(LAM) [14, 15]. The lack of additional benefit with com-
bination therapy meant that this treatment strategy was not 
pursued further and is not currently recommended in inter-
national guidelines [1]. However, the efficacy, resistance, 
and safety profiles of NAs have improved substantially since 
the initial studies with LAM and, therefore, the current study 
determined whether combining the highly potent virologi-
cal activity of TDF with immunomodulatory activity could 
provide a finite therapeutic option. The findings are scien-
tifically interesting as the rates of HBsAg loss achieved are 
substantially higher than with other therapeutic options. As 
seen in studies with PEG-IFN monotherapy, rates of HBsAg 
loss increase off therapy [16, 17] and, therefore, there is 
the potential for more patients to achieve this endpoint dur-
ing longer-term follow-up. However, the rates of HBsAg 
loss achieved are not at a level high enough to necessitate a 
change in clinical practice.
The current study initiated PEG-IFN and TDF concur-
rently; however, alternative combination strategies have 
also been investigated. Addition of PEG-IFN to entecavir 
(ETV) in HBeAg-positive virally suppressed patients 
Table 3  (continued)
Variable Group A (n = 186)
TDF + PEG-IFN for 48 weeks
Group B (n = 184)
TDF + PEG-IFN for 16 weeks, 
then TDF for 32 weeks
Group C 
(n = 185)
TDF for 
120 weeks
Group D (n = 185)
PEG-IFN for 48 weeks
All time points 
without TDF 
retreatment
(N = 186)
All time 
points on 
TDF 
retreatment
(N = 112)
All time points 
without TDF 
retreatment
(N = 184)
All time 
points on 
TDF 
retreatment
(N = 115)
Continued 
TDF treatment 
(N = 185)
All time points 
without TDF 
retreatment
(N = 185)
All time points on 
TDF retreatment
(N = 117)
 Thrombocyto-
penia
3 (2) 0 4 (2) 0 0 10 (5) 0
Patients with ALT > 400 U/L (men) or > 300 U/L (women), no./No. (%)
 On-treatment 17/186 (9) 22/112 (20) 17/184 (9) 21/115 (18) 3/185 (2) 17/185 (9) 15/117 (13)
 Off-treatment 27/186 (15) NA 27/184 (15) 0/115 NA 14/185 (8) NA
NA not applicable
a Non-serious adverse events occurring in ≥ 5% of patients
b The listed events were reported in at least 10% of patients in any study group. Not retreated includes all patients who had not reinitiated TDF at 
the time point
c Depression, depressed mood, and dysthymic disorders
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resulted in significantly greater declines in HBsAg, 
HBeAg, and HBV DNA levels than in patients remaining 
on ETV monotherapy [18]. In addition, this combination 
therapy appeared to prevent relapse after stopping ETV. 
However, HBsAg loss was not an endpoint of this study 
so a comparison with the current analysis is not possible. 
A study that did include HBsAg loss as an endpoint was 
published by Bourliére and colleagues recently [19]. Addi-
tion of PEG-IFN for 48 weeks to patients with undetect-
able HBV DNA levels for at least 1 year did not result in 
a significant increase in HBsAg loss versus NA therapy 
alone; the addition of PEG-IFN was also poorly tolerated.
The variability of the results from studies of both finite 
therapy and those investigating the benefits of combination 
therapy means that combination therapy for a set period 
of time is unlikely to be adopted in regular clinical prac-
tice for all patients. However, the results from the current 
analysis show that some patients may benefit from such 
a therapeutic approach. An analysis at week 72 of this 
data set demonstrated that patients with HBsAg decline 
from baseline to week 24 greater than 3.5 log10 IU/mL 
had a high chance of achieving HBsAg loss, while those 
with a smaller decline were highly unlikely to achieve this 
endpoint [20]. As a result, if a combination approach is 
considered, clinical decisions could be made at week 24 
about the necessity to continue the combination regimen.
The limitations of this study have been described previ-
ously. These include the exclusion of patients with bridg-
ing fibrosis or cirrhosis (due to safety concerns about the 
potential for substantial ALT flares in patients after treat-
ment discontinuation); thus, extrapolation of results to 
these patient groups is not possible. As there were only a 
small number of patients who had previously been treated 
with NAs (n = 33), there are insufficient data to assess any 
potential influence of prior HBV therapy on treatment out-
comes. In addition, a limited number of patients were in 
some of the genotype subgroups, meaning further research 
is warranted to investigate the application of these findings 
to specific genotypes [20].
The results of this analysis confirm the results from 
earlier time points which demonstrate the increased rate of 
HBsAg loss in patients treated with a finite course of PEG-
IFN plus TDF compared with the rates in patients receiv-
ing either monotherapy. This extensive data set provides 
the most robust data available to date about the potential 
benefits of combination therapy in patients with CHB. 
Although the higher rates of HBsAg loss are encouraging, 
they are not at a level that should warrant a change in clini-
cal practice. Further research is required to establish the 
most effective combination strategy and also the patients 
most likely to benefit from such an approach.
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